Rectal spacer geometry remained stable throughout five-fraction prostate SBRT
Hydrogel spacers showed no meaningful loss of geometry during prostate SBRT, supporting stable rectal separation across the treatment course.
Tag
sbrt
Simulation-free adaptive lung SBRT was feasible in the ONE STOP pilot
Eight of ten patients completed simulation-free single-fraction adaptive lung SBRT, with treatment taking a median 72 minutes.
Deformable registration substantially changed cumulative dose estimates in stereotactic re-irradiation
DIR reduced estimated liver maximum dose from 123.8 to 83.2 Gy, but accuracy deteriorated markedly for bowel and stomach.
Empty-bladder prostate SBRT met the EMPTY-RT acute safety endpoint
Empty-bladder SBRT was feasible in 85% of screened patients, with grade 2 or higher urinary toxicity of 28.1%.
SBRT controlled bone lesions but rarely delayed systemic therapy in bladder cancer
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.
Omitted guideline-recommended sectors drove local failure after sacral SBRT
Seventy-three percent of failures after nonadherent sacral contouring involved sectors that guidelines recommended including in the clinical target volume.
Respiratory gating reduced lung SBRT target volumes and normal-tissue dose
A 30–70% gating window reduced planning target volume by 34% and mean lung dose by 0.75 Gy without compromising coverage.
Cardiac-dose model validated non-cancer death risk in one lung SBRT cohort
The model calibrated well only when non-cancer death was defined consistently; an overall-survival version validated in both external cohorts.
Adaptive MR-guided prostate SBRT showed low toxicity after the early treatment peak
Grade ≥2 urinary toxicity fell from 22% at two weeks to 3% at six months, with almost no clinically significant bowel toxicity.
Protons reduced spinal cord and bowel dose in single-fraction spine SBRT plans
Proton plans preserved 20-Gy target coverage while reducing spinal cord, oesophageal, lung, and bowel dose compared with photon VMAT.
ESTRO defined minimum standards for prostate SBRT implementation
ESTRO recommends prostate SBRT for selected intermediate-risk disease with MRI-based contouring, rigorous quality assurance, and daily image guidance.
Immune-sparing lung SBRT planning reduced lymphocyte loss in a randomized phase II trial
Optimizing dose to blood- and immune-rich structures reduced lymphocyte depletion and prevented grade 3 lymphopenia after early-stage lung SBRT.
Five-fraction prostate SBRT showed low severe toxicity across Austrian centres
Linac-based 40 Gy in five fractions produced low severe toxicity and rapid urinary recovery across seven centres, although follow-up remained short.
SBRT did not reproduce brachytherapy dose escalation in gynecologic cancers
SBRT provided competitive peripheral coverage in some plans but could not consistently reproduce brachytherapy’s central dose escalation after realistic margins were applied.
Prostate reirradiation strategies remain heterogeneous despite encouraging prospective outcomes
Prospective prostate reirradiation studies reported generally acceptable toxicity, but target volumes, dose schedules and organ constraints varied substantially.